Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product

Charan Thej¹,², Balamurugan Ramadasse¹, Ankita Walvekar¹, Anish S. Majumdar¹* and Sudha Balasubramanian¹*

Abstract

Background: Mesenchymal stromal cells (MSCs) have emerged as a more beneficial alternative to conventional therapy and may offer a potential cure for unmet medical needs. MSCs are known to possess strong immunomodulatory and anti-inflammatory properties. Moreover, they promote angiogenesis and tissue regeneration through the secretion of trophic factors. For these reasons, the past decade witnessed a sharp increase in the number of clinical trials conducted with stem cells for various vascular diseases requiring angiogenesis. In this study, we evaluated the in vitro angiogenic potency of Stempeucel®, which is an allogeneic pooled human bone marrow-derived mesenchymal stromal cell (phBMMSC) product. We previously established the safety of Stempeucel® in our pre-clinical studies, and clinical trials conducted for critical limb ischaemia and acute myocardial infarction.

Methods: Because the proposed mechanism of action of phBMMSCs is mainly through the secretion of pro-angiogenic cytokines, we developed a surrogate potency assay by screening various batches of large-scale expanded phBMMSCs for the expression of angiogenic factors and cytokines through gene expression and growth factor analyses, followed by in vitro functional assays.

Results: The well characterized angiogenic vascular endothelial growth factor (VEGF) was selected and quantified in twenty six manufactured batches of phBMMSCs to establish consistency following the United States Food and Drug Administration recommendations. According to recommendations 21 CFR 211.165(e) and 211.194(a)(2), we also established and documented the specificity and reproducibility of the test methods employed through validation. Moreover, we also attempted to elucidate the mechanism of action of the cell population to ensure appropriate biological activity. The functional role of VEGF has been established through in vitro angiogenic assays and a dose-dependent correlation was observed with in vitro functional results.

(Continued on next page)
Background

Angiogenesis is a physiological process of new blood vessel formation from pre-existing vasculature, playing an orchestrated role in the growth and development of tissues and organs as well as in the process of wound healing [1]. In tissues requiring revascularization, endothelial cells migrate, proliferate and differentiate to form primitive tubular networks, which are regulated by pro-angiogenic growth factors and cytokines [2]. The primitive tubular network requires maturation and stability, which is controlled by a ‘dynamic angiogenic balance’, regulated by angiogenic stimulators and inhibitors [3]. The induction of new vasculature is stimulated either by the administration of pro-angiogenic factors through recombinant proteins/genes or by progenitor cell populations, which could secrete multiple pro-angiogenic cytokines [4]. Both of these approaches have been well tolerated, although larger clinical trial data are required to demonstrate the safety and efficacy of such therapy using optimal delivery methods [5]. Varying degrees of success in cell-based therapeutic angiogenesis have been achieved by the intramuscular administration of endothelial progenitor cells (EPCs) [6, 7], peripheral blood mononuclear cells (PBMCs) [8], bone marrow mononuclear cells (BMMNCs) [9–11] and bone marrow-derived mesenchymal stromal cells (BMMSCs) [12].

Recently, mesenchymal stromal cells (MSCs) obtained from various tissues have gained importance in regenerative medicine because of their multipotent activity, including short-term engraftment, paracrine function and differentiation to endothelial cells [13–15]. Among various tissues, BMMSCs have been extensively characterized and used in clinical studies due to their vast ex vivo expansion potential and their ability to perform multiple biological functions simultaneously to promote tissue regeneration in vivo [16]. In this study, we progressively developed an angiogenic potency assay for Stempeucel®, which consists of adult human bone marrow-derived, pooled, culture-expanded MSCs (pooled human BMMSCs (pBMMSCs)). The development and characterization of the pBMMSC population has been published previously [17–20]. Owing to the fact that striking variations have been observed in the secretome profile of different donors, we have developed a pooling technology to minimize such donor-specific variability and have generated data demonstrating that a pooled MSC population is more consistent and stable in secreting angiogenic and other cytokines that are critical for regenerative capacity of these cells in comparison with single donor-derived MSCs (Thej et al., manuscript in preparation). In addition, our published clinical trials conducted in critical limb ischaemia (CLI) patients using pBMMSCs clearly demonstrated that these pooled cells were safe [19] and therapeutically effective in patients suffering from CLI due to Buerger's disease [20].

As a global industrial standard for cell therapy products (CTPs), the development of in vitro potency assays based on the mechanism of action for a particular disease indication in large-scale expanded cells becomes essential. Potency is one of the critical quality control measures required for a CTP to demonstrate its biological activity, which should ideally be related to the intended therapeutic response. The probable mechanism of action by which MSCs elicit an angiogenic response is through their paracrine activity [14, 21]. The secretion of pro-angiogenic and vascular stability factors, such as vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), stromal-derived factor-1 (SDF-1), interleukin (IL)-8, IL-6, hepatocyte growth factor (HGF) and transforming growth factor beta-1 (TGF-β1), play a role in the recruitment of endogenous endothelial cells which subsequently undergo proliferation and differentiation into new blood vessels both in vitro and in vivo [22, 23].

In order to develop a suitable angiogenic potency assay for Stempeucel® based on the reported mechanism of action, we screened the cells for the expression of widely reported pro-angiogenic genes and further quantified the corresponding growth factors in various batches of large-scale expanded allogenic pBMMSCs. In due course we selected VEGF – a single, consistently expressed angiogenic factor and one of the most extensively studied growth factors responsible for angiogenesis – as the

**Conclusions:** The data generated from this study suggest the selection of VEGF as a single surrogate marker to test the angiogenic potency of pBMMSCs. Our study reports the quantification of VEGF in twenty six batches of large-scale manufactured pBMMSCs, and a concentration-dependent correlation of secreted VEGF to endothelial cell functions of migration, proliferation and tube formation, in the conditioned medium obtained from nine pBMMSC batches. To our cognizance, this is the first study in which a single angiogenic factor (VEGF) has been qualified as a surrogate potency marker through all three in vitro functional assays to determine the angiogenic potency of the pBMMSC population.

**Keywords:** Potency assay, Angiogenesis, Pooled human bone marrow-derived mesenchymal stromal cell, Vascular endothelial growth factor, Endothelial tube formation

(Continued from previous page)
surrogate potency marker, and further validated its mechanism of action and in vitro functional role.

Methods
Cell culture
Stempeucel® is a bone marrow-derived, ex-vivo expanded, pooled, allogeneic human MSC population that has been characterized previously [17, 24] (Additional file 1: Figure S1). Briefly, BMMNCs were separated from the bone marrow by the Ficoll density gradient method (1.077 g/ml density). BMMNCs accumulated at the buffy coat layer were plated into T-75 flasks (BD Biosciences, San Jose, CA, USA) in the medium comprising DMEM-KO (Gibco, Carlsbad, CA, USA), 10% fetal bovine serum (FBS; HyClone, Waltham, MA, USA), 100 U/ml of Penstrep (Gibco) and 100 U/ml of Glutamax (Gibco). BMMNCs from three different donors were expanded individually up to passage 1 (P1). The cells from P1 were pooled in an equal ratio and plated for expansion to sub-divid until P2. The cells were further sub-cultured up to five passages in 10 cell stacks (Corning, NY, USA). The pooled allogeneic human BMMSC population at P5 was considered Stempeucel®.

Human foreskin fibroblasts (HFFs; Lonza, Switzerland) were cultured in DMEM-KO, 10% FBS, 100 U/ml of Penstrep and 100 U/ml of Glutamax. HFFs were used for assays at P6 and P7.

Umbilical cords for isolating human umbilical vein endothelial cells (HUVECs) were obtained with the informed consent of the donors using the guidelines approved by the Institutional Committee for Stem Cell Research and Therapy and Institutional Ethics Committee at Manipal Hospital, Bangalore, India. The umbilical vein was washed three times with HBSS, and endothelial cells from the basement membrane were detached using 0.2% collagenase 1 (Sigma-Aldrich). Cells were cultured in endothelial growth medium 2 (EGM-2; Lonza), using 0.2% gelatin (Sigma-Aldrich) as an attachment substrate. The cells were characterized for endothelial markers, CD31, CD34, VE-Cadherin and Von Willebrand factor (vWF) by flow cytometry (BD LSR II; BD Biosciences) and gene expression by reverse transcriptase PCR (Additional file 2: Figure S2). All cells were grown at 37 °C in a 5% CO2 incubator (Binder, Bohemia, NY, USA).

Real-time polymerase chain reaction
Total cellular RNA was isolated using an RNeasy mini kit (Qiagen, Hilden, Germany). The RNA samples were treated with RNAase-free DNase I (Ambion, Thermo Fischer Scientific, Waltham, MA, USA) according to the manufacturer's instructions and were reverse-transcribed into cDNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The transcripts were amplified using SYBR green (Applied Biosystems). The gene-specific primers and primer sequences are presented in Table 1. A reverse transcriptase negative control was taken from each sample, and a no-template blank served as the negative control. Gene expression was normalized to the housekeeping gene β-Actin which was used as an internal standard. Subsequently, ΔΔCT was calculated against a fibroblast cell line, HFF. Similarly, VEGFR1, VEGFR2 and VEGFR3 expression in HUVECs was normalized against the same cells grown in endothelial growth medium (EGM) and expressed as the fold-change.

Preparation and collection of the conditioned medium from pHBMSCs
PHBMSCs from twenty-six different batches were thawed and plated at a density of 1 × 106 cells per T-75 flask in duplicates. The cultures were fed with 10 ml of DMEM-KO, 10% FBS, 100 U/ml of Glutamax, 100 U/ml of Penstrep and 2 ng/ml of bFGF. The conditioned medium (CM) was collected at the end of 48 and 72 h from the T-75 flasks and used for growth factor estimations and in vitro functional assays. Complete medium without cells was also incubated for 72 h and used as a control for background determination. The collected media were spun down at 1500 rpm for 5 min to eliminate cell debris, filtered through a 0.22-μm syringe filter (Merck-Millipore, NJ, USA), aliquoted and stored at –80 °C until they were used for subsequent assays.

Secretome analysis by growth factor array
The control medium and CM from six PHBMSC batches were analysed for the presence of cytokines, chemokines and growth factors by performing a semi-quantitative human growth factor antibody-based array (RayBio® Human Growth Factor Array AAH-GF-1-8; Ray Biotech, Norcross GA, USA). The experiment was performed as per the manufacturer’s instructions and chemiluminescence was recorded using ImageQuant LAS 4000 (GE Healthcare, MA, USA). The data recorded were analysed using ImageJ software (NIH). The relative intensities of individual growth factors were calculated as arbitrary units after background correction and normalized to blot intensities obtained with the control medium. The complete array layout is depicted in Additional file 3: Table S1a.

Enzyme-linked immunosorbent assay
Human angiogenic cytokines, VEGF, Ang-1, SDF-1α, IL-6, IL-8, HGF and TGF-β1 in the CM were estimated using enzyme-linked immunosorbent assay (ELISA) Kits (R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s directions. Control medium was also assayed in each ELISA; any non-specific detection of growth factors/cytokines was subtracted from the respective CM values. The samples were assayed in duplicates.

**Cell migration assay**

The cell migration assay was performed using a Transwell two-chamber cell culture method and Transwell inserts (Corning, Cambridge, MA, USA) with an 8-μm-pore polycarbonate membrane. HUVECs were serum starved for 18 h in the endothelial basal medium (EBM) supplemented with 0.1% FBS. The cells were then trypsinized and reconstituted in the serum starvation medium. Images were taken with a bright-field microscope at 100× magnification, Nikon 90" microscope). All of the assay images of three wells for each condition. The experiment was replicated for 3 biological replicates.

The serum starvation medium was replaced with equal volumes of EGM, control medium, CM, CM containing anti-VEGF neutralizing antibody (10 μg/ml) or IgG isotype control (10 μg/ml), SFM or Axitinib (0.25 nM, 0.29 nM and 1.2 nM) (Cayman Chemical, MI, USA). HUVECs were allowed to proliferate for 72 h. Then 5-bromo-2'-deoxyuridine (100 μM) was added (1:1000 in SFM) at the 48th hour, and its uptake by the cells was measured using a colorimetric cell proliferation ELISA kit (Merck-Millipore, NJ, USA).

To determine the effect of CM on VEGFR1, VEGFR2 and VEGFR3 gene expression, HUVECs were plated at a density of 5 x 10^5 cells/cm^2 in six-well dishes (BD Bioscience) in EGM. The following day, HUVECs were serum starved for 18 h in EBM supplemented with 0.1% FBS. CM from two batches of phBMMSCs were incubated alone or with anti-VEGF antibody (10 μg/ml) on HUVECs, and with EGM, which served as control. HUVECs were allowed to proliferate for 72 h. The cells were then harvested and processed further for RT-PCR analysis.

**In vitro endothelial tube formation assay**

Growth factor-reduced (GFR) Matrigel (BD Biosciences) was thawed on ice at 4 °C overnight. Ten microlitres of Matrigel was plated onto each inner well of the μ-angiogenesis slides (IBIDI, Germany) and allowed to solidify at 37 °C for 30 min. 1 x 10^4 HUVECs were reconstituted in CM only, CM containing anti-VEGF neutralizing antibody (10 μg/ml), CM with IgG isotype control (10 μg/ml), complete medium, EGM or SFM to a total volume of 50 μl and plated on the GFR Matrigel. The plates were incubated for 6 h in a humidified incubator at 5% CO_2 and 37 °C. Images were taken using an inverted phase-contrast microscope (Nikon) under 4x and 10x objectives. The tube length was measured using WimTube (Wimasis, GmbH, Germany) from the 4x magnification images of three wells for each condition. The experimental samples and controls were assayed in triplicates.

| Table 1 Primer list- Real Time PCR |
|-----------------------------------|
| **Markers** | **Forward primer** | **Reverse primer** | **Tm** | **Product length** |
|-----------|-------------------|-------------------|-------|-------------------|
| β-Actin   | CATGTACGGTGTGATCCAGGC | CTCTTAACTGCAAGCACGAT | 60    | 250bp             |
| VEGF-A    | GCCGCAATGTACGCAAGGCTG | GCATGGTGTATGGTGGCTCC | 60    | 234bp             |
| TGF-β1    | CAGATCGTGTGCAAGCGT | TCGGACGCTCTGTGATGTT | 56    | 270bp             |
| Ang-1     | GCTTACGATTCACGTCTCC | TTGCTACCTTGGCACAACAACTG | 60    | 612bp             |
| IL-6      | CACAGACAGCCACTCACCCTC | TTTTCTGCGAGTGCTCTTT | 60    | 137bp             |
| HGF       | ATGACATCAATGGTCAAGGAG | TTCATCTCACTCCCAGACT | 61    | 498bp             |
| SDF-1α/CXCL12 | TGCCAGAGCCACGTCAAG | CAGCCGGGCTGCTAACCAGAA | 60    | 73bp              |
| VEGFR1    | CGTAGAGATGTACAGTGGAAG | GGTGTGCTTTTTTGGACATC | 55    | 306bp             |
| VEGFR2    | TTACAGTCTCTCATTATTCGC | TTCTCCTCACTCCAGACAT | 60    | 498bp             |
| VEGFR3    | CTGGAAGGTTTGGGAGG | GTCACTAGAAATTGATGAGC | 60    | 138bp             |

Tm melting temperature, VEGF-A vascular endothelial growth factor A, TGF-β transforming growth factor beta, Ang-1 angiopeptin-1, IL interleukin, HGF hepatocyte growth factor, SDF-1 stromal-derived factor-1, VEGFR1 vascular endothelial growth factor receptor 1, VEGFR2 vascular endothelial growth factor receptor 2, VEGFR3 vascular endothelial growth factor receptor 3.
Statistical analysis
The data were analysed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA; http://www.graphpad.com). Pairs of data sets were analysed for statistical significance using one-way ANOVA, linear regression analysis or Student's t test (95% confidence interval). p < 0.05 was considered significant. The results were presented as means ± SEM.

Results
Screening the angiogenic predisposition of phBMMSCs
Human BMMSCs are known to express and secrete a battery of pro-angiogenic growth factors/cytokines that are necessary for neo-angiogenesis and repairing vascular damage in CLI and other ischaemic indications. Because the pooled population of human BMMSCs has been shown to increase blood flow in human clinical trials and in the pre-clinical animal models, we wanted to determine the angiogenic expression and secretion profile of our phBMMSCs. The screening of pro-angiogenic genes such as VEGF, HGF, Ang-1, SDF-1/CXCL12, IL-6, IL-8 and TGF-β1 by quantitative real time polymerase chain reaction (qRT-PCR) showed that all six batches of phBMMSCs expressed higher levels of mRNAs corresponding to VEGF (1.19 ± 0.17), HGF (409 ± 187), Ang-1 (100 ± 34.0), IL-6 (3.0 ± 1.2), IL-8 (39.0 ± 19.0) and TGF-β1 (0.59 ± 0.49) compared with the HFF cell line, which was used as control. The only exception was that the HFF cells expressed higher levels of SDF-1 mRNA than phBMMSCs (−0.44 ± 0.02). We also observed less variation in VEGF expression among the phBMMSC batches tested (Fig. 1a). The CM from the phBMMSCs (n = 6) was further evaluated for secretome profile using the growth factor array kit. We observed predominant expression of VEGF and insulin growth factor binding protein 6 (IGFBP-6) with an arbitrary unit of 20,855 ± 3566 and 22,522 ± 3528, respectively (Fig. 1b). In addition to the array analysis, we also quantified the selected angiogenic cytokines secreted by the same six batches of phBMMSCs in which the angiogenic gene expression was quantified. The cells secreted high levels of VEGF (2.6 ± 0.7 ng/ml/million cells; %CV = 25.2), HGF (31.8 ± 40 pg/ml/million cells; %CV = 78.2), SDF-1α (0.7 ± 0.54 ng/ml/million cells; %CV = 73.6), Ang-1 (1.3 ± 1.15 ng/ml/million cells; %CV = 96.6), IL-6 (6.3 ± 3.6 ng/ml/million cells; %CV = 52.4), IL-8 (18.1 ± 14.2 ng/ml/million cells; %CV = 72.2) and TGF-β1 (1.2 ± 0.3 ng/ml/million cells; %CV = 28.6) (Fig. 1c).

To determine the range of VEGF secretion by phBMMSCs in a large number of batches, we quantified the amount of VEGF in the CM from twenty six manufactured batches produced over a period of five years and several of these batches were used for pre-clinical studies and phase I and II clinical trials. The mean value of VEGF at 48 h was found to be 1.7 ± 0.7 ng/ml and that at 72 h was 2.8 ± 1.0 ng/ml for 1 × 10^6 cells plated (Fig. 2a). We also determined the robustness of the assay method by quantifying VEGF in ten batches of phBMMSCs by two different operators on the same day and by a single operator performing the assay at two different time points for the same batches of CM (Fig. 2b, c). The data showed no significant differences between the two permutations and confirmed the reproducibility and consistency of the VEGF quantification assay.

Validation of VEGF as a surrogate angiogenic potency marker for phBMMSCs
To determine the range of VEGF secretion by phBMMSCs, we first used Axitinib [25], a small molecule that is known to inhibit VEGF receptors 2, 3 and 1 at concentrations of 0.25 nM, 0.29 nM and 1.2 nM, respectively. Upon blocking the VEGF receptors, the cells were allowed to proliferate in the presence of the CM obtained from phBMMSCs: we observed 102 ± 7.7% proliferation in the 50% CM group, considering the EGM group as 100% proliferation. HUVEC proliferation in the 50% CM with Axitinib at concentrations of 0.25 nM (VEGFR2), 0.29 nM (VEGFR2, VEGFR3) and 1.2 nM (VEGFR2, VEGFR3, VEGFR1) were 6.4 ± 1.8%, 7.6 ± 0.7% and 4.9 ± 1.1% respectively; these differences were not found to be statistically significant although the highest concentration of Axitinib showed maximum inhibition of HUVEC proliferation (Fig. 3a). Because we could not determine which receptor was specifically involved in the process, we further evaluated the mRNA expression of all three VEGF receptors in the HUVECs primed with the same CM. We observed a considerable upregulation of all three VEGF receptors. However, neutralization of secreted VEGF using anti-human VEGF mAb did not abolish the expression of VEGFR1 and VEGFR3, whereas a significant downregulation of VEGFR2/KDR was evident (p = 0.01) (Fig. 3b–d).
Furthermore, an upregulation of the downstream genes, PI3K and AKT-1, was observed (Fig. 3e), thus confirming that the mechanism of VEGFR2-mediated signalling is operative for the phBMMSC population in the regulation of angiogenesis. A schematic diagram to illustrate this phenomenon is shown (Fig. 3f).

Confirmation of the functional role of VEGF through in vitro angiogenic assays

To further confirm that the VEGF secreted by phBMMSCs functionally induces angiogenesis, we performed parallel experiments using rhVEGF and the CM from the phBMMSC population. For this purpose, several HUVEC primary lines were generated and characterized for the expression of endothelial cell specific markers CD31, CD34 and vWF by flow cytometry and RT-PCR (Additional file 2: Figure S2). HUVECs harvested at P3–P5 were used for all in vitro assays. We performed HUVEC Transwell migration assays using rhVEGF solution in SFM at dilutions ranging from 8 ng/ml to 31.2 pg/ml (Fig. 4a). Except for the 8 ng/ml concentration, all other rhVEGF dilutions matched the concentration of secreted VEGF in the phBMMSC CM serially diluted from 100% (4 ng/ml VEGF) to 0.19% (7.8 pg/ml) (Fig. 4b). The 50% diluted phBMMSC CM, which contained 2 ng/ml of secreted VEGF brought about 51% greater migration than the 2 ng/ml rhVEGF (Fig. 4a, b). As expected, a dose-dependent reduction in the migrated cells was observed in both the rhVEGF and secreted VEGF groups, while the threshold concentration of VEGF necessary for HUVEC migration was determined to be 125 pg/ml. The neutralization of rhVEGF and the secreted VEGF using an anti-VEGF-blocking antibody at a concentration of 10 μg/ml inhibited HUVEC migration by 84% in the 2 ng/ml group of rhVEGF and by 85% inhibition in the 2 ng/ml secreted VEGF compared with the respective IgG isotype values. No significant difference in the migration of HUVECs was observed between the CM-treated and the isotype-treated cells (Fig. 4b).

Next, we compared the ability of rhVEGF and VEGF secreted by phBMMSCs with matched concentrations to determine the effect of VEGF in HUVEC proliferation.
The rhVEGF alone in the SFM promoted the proliferation of HUVECs (Fig. 4c); however, considerably higher proliferation was observed when the HUVECs were incubated in the presence of CM (Fig. 4d). The CM from the phBMMSCs demonstrated a dose-dependent reduction in proliferation ranging from a 50% CM containing 2 ng/ml secreted VEGF to a 0.78% CM with 31.2 pg/ml of secreted VEGF. Neutralization of the secreted VEGF using the anti-VEGF mAb at a concentration of 10 μg/ml inhibited HUVEC proliferation up to 31% as compared with CM incubated with IgG isotype, thus indicating that HUVEC proliferation was partially mediated by VEGF (Fig. 4d). Similar to the results obtained with migration, we did not observe any difference in proliferation of HUVECs when incubated with CM and CM with IgG isotype.

We further investigated the role of VEGF in the final stage of in vitro angiogenesis by performing the tube formation assay in GFR Matrigel. We observed that rhVEGF alone at concentrations ranging from 8 ng/ml to 15.6 pg/ml did not promote the tube formation of HUVECs in GFR Matrigel (data not shown). Conversely, the CM from phBMMSCs significantly promoted tube formation in a dose-dependent manner, ranging from 50% (2 ng/ml of VEGF) to the lowest concentration of 0.78% (31.2 pg/ml VEGF) where initiation of tube formation was detected (Fig. 4e–q). It should be mentioned that 2 ng/ml of VEGF containing CM showed maximum tube formation (Fig. 4r). Addition of the anti-VEGF mAb (10 μg/ml) (Fig. 4p) inhibited tube formation by >50% compared with the CM group incubated with IgG isotype. Similar to the results obtained with migration and proliferation of HUVECs, tube formation was also unaffected with the addition of the IgG isotype. Taken together, these functional studies demonstrate clearly that the VEGF present in the CM was able to elicit migration, proliferation and tube formation of HUVECs in vitro (Fig. 4).

Validation of VEGF-mediated in vitro angiogenic function by phBMMSC batches
To confirm that VEGF is indeed the angiogenic surrogate marker for the phBMMSC population, we evaluated the potential of the secreted VEGF in the CM derived from nine phBMMSC batches (Fig. 5). The biological...
The assays performed were endothelial cell migration, proliferation and tube formation, which represent the entire process of angiogenesis and correlated with the functional activity through the secreted VEGF from each batch of phBMMSCs. First, HUVEC migration was assessed using the CM from all nine batches of phBMMSCs and the results are shown in Fig. 5a, b. We observed that the cell migration was comparable amongst all batches with a 19% coefficient of variation (Fig. 5b). Upon neutralization of VEGF, the migration of HUVECs was inhibited by >75% compared with the corresponding IgG isotype (Fig. 5a).

The correlation of VEGF concentration in each of the nine batches with the number of migrated cells displayed high linearity with a correlation coefficient of 0.78 ($p = 0.0014$) (Fig. 5b).

Similarly, we also assessed the proliferation of HUVECs using all nine batches of CMs. The proliferation of HUVECs was comparable for all batches with a coefficient of variation of 21% (Fig. 5c). Neutralization of VEGF in the CM from all of the batches significantly blocked proliferation of HUVECs by >50% compared with the corresponding IgG isotype. The correlation of VEGF concentration...
quantified from these batches highly correlated with HUVEC proliferation and was calculated to generate a correlation coefficient value of 0.75 ($p = 0.002$) (Fig. 5d).

Finally, the in vitro angiogenic tube formation by HUVECs was assessed for these nine CM batches and the results are shown in Fig. 5. The extent of tube formation in all of the tested conditions are shown in Fig. 5e–i. It is clear from the representative images that the maximum tube length was observed in phBMMSC CM (Fig. 5g), phBMMSC CM with IgG isotype (Fig. 5h)
Fig. 5 (See legend on next page.)
and EGM (Fig. 5e) conditions, while complete medium and CM with anti-VEGF mAb showed similar extent of vessel formation (Fig. 5f and i respectively). Furthermore, a reduction of tube formation by >50% was observed in the presence of anti-VEGF mAb, while no such inhibition was observed with the IgG isotype (Fig. 5). The average of total tube lengths obtained from all nine batches of phBMMSC CM and other conditions are graphically represented in Fig. 5j. Similar to migration and proliferation, a strong correlation \( (r^2 = 0.8992, p = 0.0001) \) was observed between the VEGF concentration and the tube lengths (Fig. 5k) with a low CV of 18%. Collectively, the data generated by three different in vitro functional measurements of angiogenesis correlated linearly with the concentration of VEGF present in the CM generated from the phBMMSC population.

**Discussion**

Ischaemia is described as the shortage of oxygen in tissues or organs because of the restriction of blood supply instigated by vasoconstriction, thrombosis, embolism or vessel rupture in indications such as peripheral arterial disease and its more severe form, CLI [26]. In CLI patients there is extensive tissue damage due to severe blockade or degeneration of blood vessels and these patients often require therapeutic intervention using proangiogenic therapy. Moreover, CLI is associated with non-healing ulcers, gangrene and limb amputations which lead to increased morbidity and mortality rates [27]. Because conventional therapy is of limited value to these patients, attempts are being made to determine whether cell and gene therapy can provide sustainable benefit to CLI patients.

Cell-based therapeutic angiogenesis is gaining momentum as an alternative to the current revascularization strategies. Several pre-clinical and clinical studies using EPCs, autologous CD34+ BMMNCs and autologous or allogeneic MSCs derived from various tissue sources including bone marrow have demonstrated their interaction with endogenous endothelial cells via paracrine cross-talks or direct cell-to-cell interaction, thus promoting angiogenesis, resulting in limb salvage [6–8, 28]. The first clinical trial for therapeutic angiogenesis using cell transplantation (TACT) in PAD patients with autologous BMMNCs and peripheral blood mononuclear cells, conducted successfully by Tateishi-Yuyama et al. in 2002 [8], showed evidence of improvement in multiple clinical parameters in the patients injected with BMMNCs. Since then, a number of clinical trials using a variety of cell types have been completed with different degrees of success [29–32]. A trial using autologous BMMNCs showed greater clinical improvements in patients with Buerger’s disease in comparison with those with atherosclerotic PAD, and this was associated with greater EPC migration in response to VEGF in Buerger’s disease patients [33]. In our own phase I/II clinical trial where we have established the safety of phBMMSC administration in CLI patients, we also observed that there is a significant improvement in the ankle brachial pressure index (ABPI) in the cell-treated group of patients compared with placebo [19]. Recently, we have published our phase II clinical data demonstrating that intra-muscular administration of phBMMSCs in Buerger’s disease CLI patients resulted in a significant decrease in rest pain and improvements in ulcer healing and blood circulation [20]. Moreover, new collateral vessel formation was also observed in some of these patients suggesting that the cells were able to initiate neo-angiogenesis. As we progress towards a phase III clinical trial with CLI patients, in addition to developing identity, purity and safety assays, it is critical to develop an angiogenesis-specific potency assay, intended to be applied for disease indications that require therapeutic angiogenesis, to demonstrate that the expression of the ‘so-called’ potency marker by the cell product corroborates with the therapeutic outcome. Potency assay development requires establishing a clear connection between the therapeutic cells and their functional activity specific to the intended clinical indication [34]. It is necessary to develop such an assay or assay
matrix for allogeneic MSCs in a progressive manner from the pre-clinical stage through various clinical trial phases and implemented at the time of phase III trial.

The United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) accept non-functional assays for potency testing, but it is essential to develop an in vitro or in vivo biologically functional assay and attempt to correlate the potency of the product, at least to the in vitro functional assay. Correlating the potency results with the pre-clinical or clinical outcomes is usually challenging because of their complex, multimodal mechanism of action, particularly where live cells are used for treatment.

In this study, based on the existing literature supporting the therapeutic benefit of BM-MSCs in revascularization, the expression of pro-angiogenic genes was initially screened in our pooled cell population and the results clearly demonstrated their pro-angiogenic predisposition (Fig. 1). The clear demonstration of the presence of pro-angiogenic growth factors and cytokines at the gene and protein levels suggested that phBM-MSCs can be a therapeutically beneficial product for treating diseases in which tissue angiogenesis is severely impaired. Among the various factors we have screened and estimated, VEGF appears to be expressed consistently and secreted by these cells in the CM. In addition to VEGF, phBM-MSCs secrete various amounts of other well-characterized angiogenic growth factors like Ang-1, SDF-1, HGF, IL-6, IL-8 and TGF-β1. Many of these factors have been shown to have a specific role in the entire cascade of 'physiological angiogenesis,' without which adequate vascularization may not be possible [35]. The comparable levels of VEGF secretion by the phBM-MSCs across various passages suggested that the regulation of VEGF synthesis is well controlled in the manufactured phBM-MSC product (Fig. 2). These observations led us to choose VEGF as a surrogate potency marker for phBM-MSCs that has long been identified as the primary regulator of angiogenesis [36, 37]. It is noteworthy that the significance of VEGF in inducing pro-angiogenesis has not only been restricted to MSCs, because human neural stem cells (hNSCs) have also been reported to support angiogenesis in vitro and in vivo and the proposed mechanism of action is probably governed by VEGF [38]. Quantitation of VEGF on twenty-six manufactured batches over a period of five years suggested stability as well as reproducibility of VEGF secretion by the manufactured and cryopreserved phBM-MSCs; similar data pertaining to VEGF were shown earlier with Multi-stem®, a large-scale expanded multipotent adult progenitor cell (MAPC) product [39]. Based on the VEGF quantitation data obtained from many production batches (Fig. 2), the level of VEGF may be estimated to be ≥2 ng/ml/million phBM-MSCs to qualify these cells for eliciting neo-angiogenic activity.

VEGF is known to bind to its receptors, VEGFR1/Flt-1, VEGFR2/KDR and VEGFR3, with differential affinity and associated functions on EPCs [40, 41]. In order to elucidate the specificity of the receptor binding of the VEGF secreted by phBM-MSCs, we used Axitinib, a specific receptor tyrosine kinase blocker, at different concentrations to block the three VEGF receptors [25]. Our results clearly suggest that VEGF synthesized by phBM-MSCs specifically binds to VEGFR2, because >90% of VEGF binding was abolished in the presence of Axitinib at the lowest concentration of 0.25 nM, which is precisely preordained to neutralize VEGFR2 activation. Additionally, the expression of all three VEGF receptors was upregulated in the endothelial cells upon exposure to the CM from phBM-MSCs, while neutralization of the secreted VEGF in the CM significantly downregulated only VEGFR2 expression and not the other two receptors, thus indicating the specificity of VEGF secreted by the phBM-MSCs to VEGFR2. Although VEGFR2 has a lower binding affinity in comparison with VEGFR1, VEGFR2 has nevertheless been reported to be the main transducer for VEGF-A driving endothelial cell survival, migration, proliferation and their differentiation during vascular tube formation [41–43]. The survival of endothelial cells in ischaemic tissues is a key requirement in therapeutic angiogenesis, and thus we looked into the survival-related downstream molecules PI3K and AKT. In our results, we observed an increased expression of PI3K and AKT in the CM-primed endothelial cells, which further indicates the specificity of VEGF in promoting endothelial cell survival.

The contribution of VEGF was also evaluated using rhVEGF alongside the CM generated by culturing phBM-MSCs at various concentrations to understand the implication of VEGF in the angiogenic process. VEGF contributed majorly by facilitating in vitro migration, proliferation and tube formation of HUVECs (Figs 4 and 5). Biological assays along with the non-biological potency assay (e.g. ELISA) could add value to the potency evaluation of the therapeutic product, and these assays could be part of the potency assay matrix. It is also important to note that Stempeucel® has been shown to ameliorate foot necrosis and limb salvage in an in vivo murine model of hind-limb ischemia [20, 44]. Our next logical approach is to determine whether blocking VEGF immediately after Stempeucel® administration would obviate neo-angiogenesis in a felicitous pre-clinical model.

The data presented here suggest a high correlation of VEGF concentration with in vitro endothelial function, indicating that prior estimation of VEGF by ELISA can be considered a categorical, reliable and robust surrogate marker for angiogenic potency, quantifiable outside a living system, and also satisfies all regulatory requisites.
for a large-scale, expanded, allogeneic BM-MSC population, Stempeucel®.

Conclusion
In this article, we have followed a systematic approach towards developing and qualifying a potency assay as per the regulatory requirements by screening, estimating and selecting a single surrogate marker for angiogenesis. Consistency of the assay was also substantiated by establishing the reproducibility and mechanism of action as well as correlating with in vitro functional assays. Taken together, we propose that VEGF can be considered a single surrogate marker for angiogenic potency and set an example for developing and validating a potency assay for clinical-grade allogeneic phBM-MSCs intended for therapeutic angiogenesis in CLI and other vascular diseases.

Additional files

Additional file 1: Figure S1. showing a characterization of phBM-MSCs for MSC-positive surface markers (CD44, CD73, CD90, CD105 and CD166) and negative markers (CD14, CD19, CD34, CD45, CD33 and HLA-DR), and indication of viability (inset), by flow cytometry. b differentiation of phBM-MSCs into adipocytes, osteocytes and chondrocytes, stained with Oil Red O, Alizarin Red S and Saffronin O, respectively. (TIF 6151 kb)

Additional file 2: Figure S2. showing a morphology of HUVECs at P1; b–d characterization of HUVECs using three-colour flow cytometry analysis for surface markers CD31, CD34 and CD73 indicating high HUVEC purity; e characterization of HUVECs by reverse transcriptase PCR for endothelial specific markers, vWF (von Willebrand factor), VE-Cadherin, CD34 and CD31. (TIF 3909 kb)

Additional file 3: Table S1a. presenting the layout of a chemiluminescence detection-based growth factor array for Fig. 1b; information provided for the manufacturer. (TIF 1976 kb)

Abbreviations
ABPI: Acute brachial pressure index; AKT/PKB: Protein kinase B; Ang-1: Angiopoietin-1; BFGF: Basic fibroblast growth factor; BM-MNC: Bone marrow mononuclear cell; CLI: Critical limb ischaemia; CTP: Cell therapy product; DMEM-KO: Dulbecco’s modified Eagle medium, knockout; EBM: Endothelial basal medium; EGM: Endothelial growth medium; ELISA: Enzyme-linked immunosorbent assay; EMA: European Medicines Agency; EPC: Endothelial progenitor cell; FBS: Fetal bovine serum; GFR: Growth factor reduced; HFF: Human foreskin fibroblast; HGF: Hepatocyte growth factor; HUVEC: Human umbilical vein endothelial cell; IGFIP-6: Insulin like growth factor binding protein-6; IL: Interleukin; mAb: Monoclonal antibody; MAPC: Multipotent adult progenitor cell; MNC: Mononuclear cell; MSC: Mesenchymal stromal cell; PAD: Peripheral arterial disease; PB-MNC: Peripheral blood mononuclear cell; phBM-MSC: Pooled human bone marrow-derived mesenchymal stromal cell; PI3K: Phosphoinositide-3-kinase; qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction; rhVEGF: Recombinant human vascular endothelial growth factor; SDF-1: Stromal-derived factor-1; TACT: Therapeutic angiogenesis using cell transplantation; TGF-B1: Transforming growth factor beta-1; US FDA: United States Food and Drug Administration; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; VWF: Von Willebrand factor

Acknowledgements
The authors thank Mr. Manohar for funding this study, Ms Devi and Mr Pachaiyappan of the production team for providing the Stempeucel® batches, Dr Uday Kolikkad, Dr Swathi Sundararaj and Dr Pawan K. Gupta for their valuable suggestions during the course of the study, Dr Anoop Chullikana for his help with statistical analysis and Ms Priyanka Swamy Nathan for her help in preparation of the manuscript.

Funding
The study was funded by Stempeutics Research Pvt. Ltd, Bangalore, India.

Availability of data and materials
Data supporting the manuscript have been uploaded in the form of supplementary material.

Authors’ contributions
CT was responsible for conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. BR was responsible for collection and/or assembly of data. AW was responsible for conception and design, data analysis and interpretation, and final approval of the manuscript. SB was responsible for conception and design, assembly of data, data analysis and interpretation, manuscript writing and final approval. All authors read and approved the manuscript.

Authors’ information
CT is Senior Research Associate, Stempeutics Research Pvt. Ltd and PhD scholar, Manipal University. BR is Manager in Quality Control, Stempeutics Research Pvt. Ltd. AW is Research Associate, Stempeutics Research Pvt. Ltd. ASM is Executive Vice President & Chief Scientific Officer, Stempeutics Research Pvt. Ltd. SB is Principal Scientist, Stempeutics Research Pvt. Ltd.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All participating authors consent to the publication of this article.

Ethics approval and consent to participate
All human tissues were obtained with written informed consent using the guidelines approved by the Institutional Committee for Stem Cell Research and Therapy (ICSCRT) and the Institutional Ethics Committee (IEC) at the Manipal Hospital, Bangalore, India. The study was also approved by both the committees.

Author details
1Stempeutics Research Pvt. Ltd, Akshay Tech Park, #72 & 73, 2nd Floor, EPfIP Zone, Phase 1, Bangalore, Whitefield 560066, India. 2Manipal University, Manipal, Karnataka, India.

Received: 10 August 2016 Revised: 7 December 2016 Accepted: 24 January 2017 Published online: 28 February 2017

References
1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–4.
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.
3. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997;78:672–7.
4. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg. 2004;28:89–23.
5. Vale PR, Losordo DW, Symes JF, Imer MM. Growth factors for therapeutic angiogenesis in cardiovascular diseases. Rev Esp Cardiol. 2001;54:210–24.
6. Kawamoto A, Katayama M, Handa N, Kinosita M, Takano H, Horii M, et al. Intramuscular transplantation of G-CSF-normalized CD34(+) cells in patients with critical limb ischemia: a phase IIa multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27:2857–64.
7. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012;5:821–30.
8. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.
9. Miyamoto K, Nishigami K, Nagaya N, Akutsu K, Chiku M, Kamei M, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114:2679–84.

10. Dardzins S, Akar AR, Arat M, Sancak T, Eren NT, Ozyardı U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II–III thromboangiitis obliterans. J Vasc Surg. 2006;44:732–9.

11. Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011;53:1556–74.e1.

12. Lu D, Chen S, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26–36.

13. Von Bahr L, Batsi I, Moll G, Hägg M, Szokás A, Sundberg B, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30:1575–8.

14. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10:244–58.

15. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377–83.

16. Hoffmann AM, Dow SW. Concise review: Stem cell trials using companion allogeneic mesenchymal stromal cells in critical limb ischemia due to atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv. 2011;4:15–25.

17. Cameri J, Burger SR, McCammon M, Rowley JA. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen Med. 2012;7:85–100.

18. Costa-Almeida R, Gomez-Lazaro M, Ramalho C, Granja PL, Soares R, Guerrero SG, Fibroblast-endothelial partners for vascularisation strategies in tissue engineering. Tissue Eng Part A. 2015;21:1055–65.

19. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56:794–814.

20. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.

21. Katare R, Stroemer P, Hicks C, Stevanato L, Patel S, Corteling R, et al. Clinical-grade human neural stem cells promote reparative neovascularization in mouse models of hindlimb ischemia. Anesthesiol Thromb Vasc Biol. 2014;34:408–18.

22. Lehman N, Cutrone R, Raber A, Perry R, Van’t Hof W, Deans R, et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. 2012;14:994–1004.

23. Hobbelen AN, Cripps RJ, Heggler S, Oosterom ATV, Bruijn EA, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549–80.

24. Grünewald FS, Prata AE, Giese A, Ballmer-Hofer K. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. 2012;14:994–1004.

25. Fakharuzi NA, et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem. 2012;113:315–64.

26. Chullikana A, Majumdar A Sen, Gottipamula S, Krishnamurthy S, Kumar AS, Prakash VS, et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy. 2015;17:250–61.

27. Gupta PK, Chullikana A, Panahi R, Desai S, Das A, Gottipamula S, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013;11:143.

28. Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, et al. Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger’s disease: phase II study report suggests clinical efficacy. Stem Cells Transl Med. 2016. [Epub ahead of print].

29. Singar NG. Fibroblast-endothelial partners for vascularization strategies in tissue engineering. Annu Rev Pathol. 2011;6:457–78.

30. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648–59.

31. Patel AN, Genovese J. Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy. Stem Cells Cloning. 2011;461–72.

32. Pal R, Hanwate M, Jan M, Totey S. Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med. 2009;3:163–74.

33. Escudier B, Gore M. Avitabin for the management of metastatic renal cell carcinoma. Drugs R D. 2011;11:113–26.

34. Ernst E. Periocular vasculature. BMJ. 1989;299:873.

35. Das AK, Gupta PK, Anoop CH, Balasubramanian S, Majumdar AS. Mesenchymal Stem Cell Therapy for Peripheral Vascular Diseases. In: Mesenchymal Stem Cell Therapy. Totowa: Humana Press; 2013. p. 405–21.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit